Please use this identifier to cite or link to this item: http://localhost:80/xmlui/handle/123456789/13770
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLUQMAN, ASIMA-
dc.contributor.authorREHMAN, WAJIH-UR--
dc.contributor.authorRASOOL, SOHAIL ATTAUR-
dc.contributor.authorRAZA, HASHIM-
dc.contributor.authorHUSSAIN, SADIQ-
dc.contributor.authorLUQMAN, SHOAIB-
dc.date.accessioned2022-10-27T03:30:48Z-
dc.date.available2022-10-27T03:30:48Z-
dc.date.issued2018-10-
dc.identifier.issn1996-7195-
dc.identifier.urihttp://142.54.178.187:9060/xmlui/handle/123456789/13770-
dc.description.abstractAim: Gallbladder carcinoma (GBC) commonly present at an advanced unresectable stage. We sought to compare efficacy of gemcitabine alone and in combination with radiotherapy as adjuvant treatment of GBC. Study Design: Quasi-experimental study. Place & Duration of Study: Nishtar Hospital Multan from July 2012 to June 2013. Methods: Fourty six confirmed cases of unresectable GBC were randomly allocated in two groups. Group-I received gemcitabine alone and Group-II received gemcitabine and radiotherapy. Results: Combination of gemcitabine and radiotherapy achieved better clinical efficacy as adjuvant treatment. Conclusions: Radiation therapy using Gemcitabine as radiosensitizer is more beneficial in control of disease.en_US
dc.language.isoen_USen_US
dc.publisherPakistan Journal of Medical and Health Sciencesen_US
dc.subjectGallbladder carcinomaen_US
dc.subjectgemcitabineen_US
dc.subjectradiotherapyen_US
dc.titleClinical Efficacy of Adjuvant Therapy in Unresectable Gallbladder Cancer: our experience from south Punjaben_US
dc.typeArticleen_US
Appears in Collections:Oct-Dec,2018,Issue(4)

Files in This Item:
File Description SizeFormat 
1614.htm120 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.